-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $204

Benzinga·12/16/2025 14:35:43
语音播报
Canaccord Genuity analyst Whitney Ijem maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $148 to $204.